Comparing ContraVir Pharmaceuticals (CTRV) and NeuroDerm (NDRM)

ContraVir Pharmaceuticals (NASDAQ: CTRV) and NeuroDerm (NASDAQ:NDRM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.


This table compares ContraVir Pharmaceuticals and NeuroDerm’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ContraVir Pharmaceuticals N/A -856.04% -99.77%
NeuroDerm N/A -38.82% -36.88%

Analyst Recommendations

This is a summary of recent ratings and price targets for ContraVir Pharmaceuticals and NeuroDerm, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ContraVir Pharmaceuticals 0 0 2 0 3.00
NeuroDerm 0 3 5 0 2.63

ContraVir Pharmaceuticals currently has a consensus price target of $4.00, indicating a potential upside of 565.45%. NeuroDerm has a consensus price target of $45.86, indicating a potential upside of 17.88%. Given ContraVir Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe ContraVir Pharmaceuticals is more favorable than NeuroDerm.

Insider and Institutional Ownership

10.0% of ContraVir Pharmaceuticals shares are held by institutional investors. Comparatively, 52.4% of NeuroDerm shares are held by institutional investors. 3.3% of ContraVir Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares ContraVir Pharmaceuticals and NeuroDerm’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
ContraVir Pharmaceuticals N/A N/A -$21.00 million ($0.49) -1.23
NeuroDerm N/A N/A -$49.04 million ($1.98) -19.65

NeuroDerm is trading at a lower price-to-earnings ratio than ContraVir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

ContraVir Pharmaceuticals has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Comparatively, NeuroDerm has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.


ContraVir Pharmaceuticals beats NeuroDerm on 6 of the 10 factors compared between the two stocks.

ContraVir Pharmaceuticals Company Profile

ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100. The Company’s CMX157 is a lipid acyclic nucleoside phosphonate that delivers intracellular concentrations of the active antiviral agent tenofovir diphosphate. The Company has completed a Phase I clinical trial of CMX157. The Company’s CRV431 drug candidate is designed to target cyclophilins, which are a class of proteins. CRV431 inhibits the role of host cyclophilins and interferes in the propagation of the viruses. The Company’s FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743, which is used for the treatment of herpes zoster. The Company has developed FV-100 for the treatment of shingles.

NeuroDerm Company Profile

NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701. It is developing ND0612H for the treatment of patients suffering from severe Parkinson’s disease. It is developing ND0612L for the treatment of patients at the moderate stage of Parkinson’s disease that can no longer control motor complications with oral levodopa. It has also designed ND0701, which is an apomorphine-based product. ND0701 is for patients suffering from Parkinson’s disease, may be used mostly by patients suffering from high motor fluctuations and not responding well to LD/CD.

Receive News & Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply